Commercial Supply Bedaquiline Related Intermediates:
3-Benzyl-6-Bbromo-2-Mmethoxyquinoline CAS: 654655-69-3
3-Benzyl-6-Bromo-2-Chloroquinoline CAS: 654655-68-2
3-(Dimethylamino)-1-(Naphthalen-1-yl)propan-1-one Hydrochloride CAS: 5409-58-5
Bedaquiline CAS: 843663-66-1
Bedaquiline Fumarate CAS: 845533-86-0
| Chemical Name | 3-Benzyl-6-Bromo-2-Chloroquinoline |
| Synonyms | 6-Bromo-2-Chloro-3-(Phenylmethyl)quinoline; Bedaquiline Impurity B; Bedaquiline Fumarate Impurity 5 |
| CAS Number | 654655-68-2 |
| CAT Number | RF-PI107 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C₁₆H₁₁BrClN |
| Molecular Weight | 332.62 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White or Light Yellow Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Melting Point | 100.0~120.0℃ |
| Moisture (K.F) | ≤0.50% |
| Residue on ignition | ≤0.50% |
| Test Standard | Enterprise Standard |
| Usage | Bedaquiline Fumarate (CAS: 845533-86-0) Intermediate |
3-Benzyl-6-bromo-2-chloroquinoline CAS: 654655-68-2 is a main intermediate of Bedaquiline.
Bedaquiline Fumarate is a diarylquinone drug developed by Janssen Pharmaceutical. The drug, which was approved in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB), was developed in partnership with Johnson & Johnson and represents the first new tuberculosis therapy approved in over four decades. Bedaquiline is the first member of a new class of diarylquinone compounds whose mechanism of action inhibits Mycobaterium tuberculosis ATP synthase which deprives bacterium of energy.
Bedaquiline Fumarate used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of th mycobacteria.